Latest Breaking News On - Cardiac amyloidosis - Page 1 : comparemela.com

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

United kingdomCity ofUnited statesAhmad masriEuropean society of cardiology congressCytokinetics incorporated nasdaqEuropean societyCardiology congressObstructive hypertrophic cardiomyopathyHypertrophic cardiomyopathy centerOregon healthInfiltrative myocardialCardiac amyloidosis

The Genetic Risk: V142I Variant and Heart Failure Among Black Americans

The Genetic Risk: V142I Variant and Heart Failure Among Black Americans
medindia.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medindia.net Daily Mail and Mail on Sunday newspapers.

United statesSenthil selvarajEdwardd frohlichWomen health initiativeDuke universityDuke university school of medicineHarvard medical schoolBlack americansCardiac amyloidosisDistinguished chairHarvard medicalHealth initiativeDuke university schoolTransthyretin variant

Kaiser Permanente Awards Funding for Healthcare AI, ML Research

Kaiser Permanente Awards Funding for Healthcare AI, ML Research
healthitanalytics.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healthitanalytics.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesVanderbilt universitySan ysidroFatima munozLos angelesCesar termulo jrStephenm parodiDavid ouyangVincent liuSivasubramanium bhavaniShania kennedySinai medical centerSan ysidro healthEmory university in atlantaParkland health

Patisiran prevents functional decline in patients with cardiac amyloidosis

1. In this randomized controlled trial, patisiran demonstrated a reduction in functional capacity decline transthyretin amyloidosis (ATTR amyloidosis) with a cardiac component as compared to placebo. 2. Compared to placebo, patisiran demonstrated a higher rate of infusion-related reactions, arthralgias, and muscle spasms. Evidence Rating Level: 1 (Excellent) Study Rundown: ATTR amyloidosis is a serious condition

Minute medicine incRating levelKansas city cardiomyopathy questionnaireOverall summaryAmyloid fibrilsAttr amyloidosisCardiac amyloidosisChronic diseaseTransthyretin amyloidosisTransthyretin amyloidosis attr

Novel Amyloid Drug Improves Mid-Term Outcomes in ATTR Cardiomyopathy

Pivotal trial 'suggests the tantalizing possibility of genuine clinical improvement'

France generalNoord hollandReferral centerUniversity hospital henri mondorPpeuropean society of cardiologyYork heart associationEuropean society of cardiologyThibaud damyCardiac amyloidosisNew york heart association